Perhaps so, as federal and state programs look more to private insurers to help control spending.
Is the managed care backlash over? Perhaps so, as federal and state programs look more to private insurers to help control spending while providing quality care.
This development is somewhat surprising, as MA rate cuts authorized by the Patient Protection and Affordable Care Act (PPACA) threatened to spark a plan exodus.
Only nine of 570 MA plans achieved the five-star score in the CMS rating report for 2012 unveiled in October, while about 95 plans received four or more. These plans should grow because they may market and enroll members year-round.
However, more than 50% of MA enrollees are in the 264 plans that fell into the three star range, a level that provides a small bonus this year, but not in the future. These plans, along with some 150 plans rated below the three-star level, are under pressure to improve quality very quickly or face expulsion from the Medicare program. Leading insurers say they're investing in systems and programs designed to improve care and are serious about boosting star ratings in order to expand their programs and gain higher payments from CMS.
STATES BOOST MANAGED CARE
Meanwhile, managed care is helping state officials deal with soaring costs and diminished resources. The end of enhanced federal stimulus funds in July, coupled with rising Medicaid enrollment, has sent states scrambling for money-saving ideas. PPACA prevents states from reducing Medicaid eligibility, forcing them to boost co-pays, cut rates to hospitals and physicians and eliminate extra benefits to maintain viable healthcare programs.
Another strategy is to adopt or expand Medicaid managed care. This year, 17 states expanded managed care programs, and 24 states said they would do so next year, according to a survey by the Kaiser Family Foundation. Many states are extending managed care to additional regions or populations, such as the disabled, dual-eligibles and even long-term care patients. Several prominent states-New Jersey, New York, Texas-have major managed care initiatives underway.
Program administrators for both Medicare and Medicaid are eyeing managed care programs as key to promoting quality measurement and performance improvement strategies. The prospect of additional federal budget cuts may further spur the shift to managed care-and test whether insurers can deliver high-quality care with less money.
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More